NASDAQ:EIGR

Eiger BioPharmaceuticals Stock Forecast, Price & News

$10.44

-0.51 (-4.66 %)

(As of 02/25/2021 12:00 AM ET)

Add

Compare

Today's Range

$10.26

Now: $10.44▼

$11.02

50-Day Range

$9.61

MA: $11.08▼

$12.30

52-Week Range

$4.55

Now: $10.44▼

$13.99

Volume173,775 shs

Average Volume312,009 shs

Market Capitalization$339.63 million

P/E RatioN/A

Dividend YieldN/A

Beta1.54

Eiger BioPharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase 3 clinical trial to treat hepatitis delta virus (HDV) infection. The company's product candidate also include Lambda, which targets type III interferon receptors that is in Phase 2 clinical trial; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide that has completed phase 2 clinical trial to treat post-bariatric hypoglycemia, as well as in phase 2 clinical trial for the treatment of congenital hyperinsulinism. The company is headquartered in Palo Alto, California.

Headlines

Eiger Bio's Avexitide Shows Reduced Rates Of Hypoglycemia, Rescue In Outpatient Setting
February 23, 2021 | finance.yahoo.com

Eiger Announces Publication of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia in Journal of Clinical Endocrinology & Metabolism
February 23, 2021 | finance.yahoo.com

Eiger BioPharmaceuticals Announces US Commercial Availability Of Zokinvy For Progeria And Processing-Deficient Progeroid Laminopathies
January 26, 2021 | benzinga.com

Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy™ (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies
January 25, 2021 | finance.yahoo.com

Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans
January 7, 2021 | finance.yahoo.com

Eiger Looks Like A Solid Long-Term Play After Zokinvy's Approval
November 30, 2020 | seekingalpha.com

FDA Approves Eiger Biopharma's Progeria Treatment: What Investors Should Know
November 23, 2020 | msn.com

Eiger Bio (EIGR) rises 8% on sale of priority review voucher for $95M
November 23, 2020 | seekingalpha.com

Eiger BioPharmaceuticals Sells Priority Review Voucher for $95 Million
November 23, 2020 | finance.yahoo.com

First therapy for childhood aging disease wins FDA approval
November 21, 2020 | bizjournals.com

Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy™ (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
November 20, 2020 | finance.yahoo.com

The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger
November 20, 2020 | msn.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:EIGR

Previous Symbol

CUSIPN/A

CIK1305253

Webwww.eigerbio.com

Phone650-272-6138

Employees29

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.27

Current Ratio6.23

Quick Ratio6.23

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.31 per share

Price / Book4.52

Profitability

EPS (Most Recent Fiscal Year)($3.08)

Net Income$-70,250,000.00

Net MarginsN/A

Return on Equity-100.60%

Return on Assets-57.76%

Miscellaneous

Outstanding Shares32,532,000

Market Cap$339.63 million

Next Earnings Date3/12/2021 (Estimated)

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.61 out of 5 stars

Medical Sector

298th out of 1,957 stocks

Biological Products, Except Diagnostic Industry

38th out of 177 stocks

3.5 Analyst's Opinion

Consensus Rating
Eiger BioPharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $25.00, Eiger BioPharmaceuticals has a forecasted upside of 139.5% from its current price of $10.44.
Amount of Analyst Coverage
Eiger BioPharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.9 Community Rank

Outperform Votes
Eiger BioPharmaceuticals has received 410 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Eiger BioPharmaceuticals has received 289 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Eiger BioPharmaceuticals has received 58.66% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Eiger BioPharmaceuticals and other stocks. Vote “Outperform” if you believe EIGR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EIGR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Eiger BioPharmaceuticals does not currently pay a dividend.
Dividend Growth
Eiger BioPharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eiger BioPharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,739.00 in company stock.
Percentage Held by Insiders
Only 5.80% of the stock of Eiger BioPharmaceuticals is held by insiders.
Percentage Held by Institutions
68.77% of the stock of Eiger BioPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Eiger BioPharmaceuticals are expected to decrease in the coming year, from ($1.36) to ($1.61) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eiger BioPharmaceuticals is -4.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eiger BioPharmaceuticals is -4.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Eiger BioPharmaceuticals has a P/B Ratio of 4.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$10.44

-0.51 (-4.66 %)

(As of 02/25/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive EIGR News and Ratings via Email

Sign-up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter.

Eiger BioPharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions

Is Eiger BioPharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Eiger BioPharmaceuticals stock.
View analyst ratings for Eiger BioPharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Eiger BioPharmaceuticals?

Wall Street analysts have given Eiger BioPharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Eiger BioPharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Eiger BioPharmaceuticals' next earnings date?

Eiger BioPharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021.
View our earnings forecast for Eiger BioPharmaceuticals.

How were Eiger BioPharmaceuticals' earnings last quarter?

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) released its earnings results on Thursday, November, 5th. The biotechnology company reported ($0.52) EPS for the quarter, beating the Zacks' consensus estimate of ($0.61) by $0.09.
View Eiger BioPharmaceuticals' earnings history.

How has Eiger BioPharmaceuticals' stock price been impacted by Coronavirus?

Eiger BioPharmaceuticals' stock was trading at $6.81 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EIGR shares have increased by 53.3% and is now trading at $10.44.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for EIGR?

2 analysts have issued 12 month target prices for Eiger BioPharmaceuticals' stock. Their forecasts range from $22.00 to $28.00. On average, they expect Eiger BioPharmaceuticals' share price to reach $25.00 in the next twelve months. This suggests a possible upside of 139.5% from the stock's current price.
View analysts' price targets for Eiger BioPharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Eiger BioPharmaceuticals' key executives?

Eiger BioPharmaceuticals' management team includes the following people:

Mr. David A. Cory R.Ph, MBA, Bus. Founder, Pres, CEO & Director (Age 57, Pay $862.03k)
Dr. Jeffrey S. Glenn, Founder, Scientific Advisor & Independent Director (Age 58, Pay $53.5k)
Mr. Sriram Ryali M.B.A., Chief Financial Officer (Age 40, Pay $461.98k)
Dr. Stephana E. Patton, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 50, Pay $417.8k)
Dr. Evan Loh, CEO of Paratek Pharmaceuticals & Director (Age 62, Pay $56k)
Mr. Eldon C. Mayer III, M.B.A., Exec. VP & Chief Commercial Officer (Age 60, Pay $55.5k)
Dr. Ingrid C. Choong, Sr. VP of Clinical Devel.
Mr. James P. Shaffer MBA, Chief Bus. Officer (Age 54)
Mr. Rich Franco M.B.A., Sr. VP & Progeria Program Lead
Dr. Colin Hislop, Sr. VP of Clinical & Devel. Operations (Age 63)

Who are some of Eiger BioPharmaceuticals' key competitors?

Some companies that are related to Eiger BioPharmaceuticals include Atara Biotherapeutics (ATRA), Vaxcyte (PCVX), Adverum Biotechnologies (ADVM), Mesoblast (MESO), Coherus BioSciences (CHRS), Aligos Therapeutics (ALGS), Black Diamond Therapeutics (BDTX), Taysha Gene Therapies (TSHA), Inhibrx (INBX), Cortexyme (CRTX), Adaptimmune Therapeutics (ADAP), TCR2 Therapeutics (TCRR), Cellectis (CLLS), Sutro Biopharma (STRO) and Vaxart (VXRT).
View all of EIGR's competitors.

What other stocks do shareholders of Eiger BioPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO).

What is Eiger BioPharmaceuticals' stock symbol?

Eiger BioPharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Who are Eiger BioPharmaceuticals' major shareholders?

Eiger BioPharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.30%), Northern Trust Corp (1.33%), P.A.W. Capital Corp (1.23%), Laurion Capital Management LP (0.77%), Trellus Management Company LLC (0.63%) and JPMorgan Chase & Co. (0.63%). Company insiders that own Eiger BioPharmaceuticals stock include Eldon C Mayer III, Jeffrey S Glenn, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz.
View institutional ownership trends for Eiger BioPharmaceuticals.

Which major investors are selling Eiger BioPharmaceuticals stock?

EIGR stock was sold by a variety of institutional investors in the last quarter, including Caxton Corp, DRW Securities LLC, Barclays PLC, and Russell Investments Group Ltd..
View insider buying and selling activity for Eiger BioPharmaceuticals or view top insider-selling stocks.

Which major investors are buying Eiger BioPharmaceuticals stock?

EIGR stock was acquired by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, BlackRock Inc., State of Wisconsin Investment Board, Squarepoint Ops LLC, P.A.W. Capital Corp, Dfpg Investments LLC, Engineers Gate Manager LP, and Nuveen Asset Management LLC. Company insiders that have bought Eiger BioPharmaceuticals stock in the last two years include Eldon C Mayer III, Jeffrey S Glenn, Sriram Ryali, Stephana Eilene Patton, and Thomas John Dietz.
View insider buying and selling activity for Eiger BioPharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Eiger BioPharmaceuticals?

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eiger BioPharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $10.44.

How much money does Eiger BioPharmaceuticals make?

Eiger BioPharmaceuticals has a market capitalization of $339.63 million. The biotechnology company earns $-70,250,000.00 in net income (profit) each year or ($3.08) on an earnings per share basis.

How many employees does Eiger BioPharmaceuticals have?

Eiger BioPharmaceuticals employs 29 workers across the globe.

What is Eiger BioPharmaceuticals' official website?

The official website for Eiger BioPharmaceuticals is www.eigerbio.com.

Where are Eiger BioPharmaceuticals' headquarters?

Eiger BioPharmaceuticals is headquartered at 2155 PARK BOULEVARD, PALO ALTO CA, 94306.

How can I contact Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]

This page was last updated on 2/26/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here